Biopharmaceutical companies are active in IPOs, and another batch of pharmaceutical companies have filed applications

In 2020, biopharmaceutical companies are active in IPOs, and the number of IPOs completed has reached a recent high.
trend continues in 2021, with five more companies recently filing ipos to land on NASDAQ.
the five companies are Vor Biopharma, which is dedicated to the development of acute myeloid leukemia (AML) and other blood cancer cell therapies, Terns Pharmaceuticals, which specializes in the development of new treatments for chronic liver diseases such as NASH, liver fibrosis and hepatocellular carcinoma, Immunocore, which focuses on innovative cancer therapies, and Bolt Biotherapeutics, a cancer immunotherapy company.
it is worth noting that all five companies are committed to the development of innovative cancer therapies.
addition to foreign biopharmaceutical companies, in fact, in the domestic biopharmaceutical companies to declare the IPO application is also very active.
, according to Wind, more than 100 biopharmaceutical companies will try to land on the board by 2020, accounting for more than 20 percent of the company's filing companies.
from the company, 17 biopharmaceutical companies had successfully listed as of June 11, 2020, after filing an IPO application.
it is understood that a group of biopharmaceutical enterprises that have declared the IPO of the Company are mainly involved in innovative pharmaceutical research and development, innovative pharmaceutical services, original drugs, in-body diagnostic products and many other sub-sectors.
such as December 18, the Southern Model Biological Application Section of the board listing has been accepted. according to
data, Nanmoor Bio is a cutting-edge gene editing technology application and innovation as the guide, focusing on the provision of genetic modification model biological research and development, production, sales and customized services of biotechnology companies, mainly engaged in genetic modification animal model products and technical services related business.
same day, JiaTron Bio application for the listing of the board was also accepted, Hualong Securities for its sponsor. according to the
prospectus, JiaTron Bio is a high-tech enterprise that provides cell building and storage, cell verification, virus removal/inactivation verification and corresponding biosecurity assessment third-party services for biological products enterprises, medical institutions and research institutes, and its main business is cell quality testing and biosecurity assessment of biological products.
overall, we can see that the inclusiveness of the Board is being further reflected.
this background, the industry expects that in the future, attracted by the significant industrial aggregation effect of the board, as well as higher valuation levels and other factors, will also promote more small and medium-sized biopharmaceutical enterprises to log on to the board.
fact, the biopharmaceutical industry as a strategic emerging industry, in the GEM registration system reform landing and other good policies, this has embarked on the fast track of industrial development.
as China's epidemic prevention and control continues to improve and the market continues to pick up, the industry expects both the number of IPOs and the size of the fund-raising to increase in 2021.
But it is worth noting that, compared with traditional pharmaceutical companies, biopharmaceutical enterprises generally have weak integration capabilities throughout the field, usually in the sub-sector of research and development accumulation, in the depth of research in specific technologies have an advantage.
, industry insiders believe that the focus of future investors on bioinnovating pharmaceutical companies may shift from pipelines to "pipelines and top-line".
for biopharmaceutical companies, the composition of future competitiveness will be multi-faceted, in addition to strengthening the innovation of the product itself, but also to continuously optimize pricing strategy, sales capacity and so on.